1. Gajer G. Jelektronnaya gistohimiya. M.: Mir; 1974.
2. Gluwenko E.V., Zaec T.L., Serov G.G. Dinamika sinteza fibronektina fibroblastami cheloveka v kul'ture. Bjul. jeksperiment. biol.i med. 1996; 5: 575-7.
3. Gavriljuk B.K. Kul'tura kletok i rekonstrukciya tkanej (na primere kozhi). Puwino: AN SSSR, NCBI, IBF; 1988: 123.
4. Zlatopol'skij A.D., Chubkina A.N., Zajdenberg M.A. Vliyanie fermentov fibronektina na proliferativnuju aktivnost' fibroblastov. Biohimiya 1989; 54(1): 74-9.
5. Marinkovich М.Р., Keene D.R., Rimberg C.S., Burgeson R.E. Cellular origin of the dermal-epidermal basement membrane. Dev. Dyn. 1993; 197(4): 255-67.
6. Sorrell J.M., Baber M.A., Caplan A.I. Site-matched papillary and reticular human dermal fibroblasts differ in their release of specific growth factors/cytokines and in their interaction with keratinocytes. J. Cell Physiol. 2004; 200(1): 134-45.
7. Konig A., Lauharanta J., Bruckner-Tuderman L. Keratinocytes and fibroblasts from a patient with mutilating dystrophic epidermolysis bullosa synthesize drastically reduced amounts of collagen VII: lack of effect of transforming growth factor-beta. J. Invest. Dermatol. 1992; 99(6): 808-12.
8. Kane C.J., Hebda P.A., Mansbridge J.N., Hanawalt P.С Direct evidence for spatial and temporal regulation of transforming growth factor beta 1 expression during cutaneous wound healing. J. Cell Physiol. 1991; 148(1): 157-73.
9. Igarashi A., Okochi H., Bradham D.M., Grotendorst G.R. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol. Biol. Cell. 1993; 4(6): 637-45.
10. Boxman I., Lowik C, Aarden L, Ponec M. Modulation of IL-6 production and IL-1 activity by keratinocyte-fibroblast interaction. J. Invest. Dermatol. 1993; 101(3): 316-24.
11. Marchese C, Felici A., Visco V. et al. Fibroblast growth factor 10 induces proliferation and differentiation of human primary cultured keratinocytes. J. Invest. Dermatol. 2001; 116(4): 623-8.
12. Werner S., Beer H.D., Mauch С et al. The Mad1 transcription factor is a novel target of activin and TGF-beta action in keratinocytes: possible role of Mad1 in wound repair and psoriasis. Oncogene 2001; 20(51): 7494-504.
13. Blomrme E.A., Sugimoto Y, Lin Y.C. et al. Parathyroid hormone-related protein is a positive regulator of keratinocyte growth factor expression by normal dermal fibroblasts. Mol. Cell Endocrinol. 1999; 152(1 - 2): 189-97.
14. Maas-Szabowski N., Shimotoyodome A., Fusenig N.E. Keratinocyte growth regulation in fibroblast cocultures via a double paracrine mechanism. J. Cell Sci. 1999; 112(12): 1843-53.
15. El Ghalbzouri A., Lamme E., Ponec M. Crucial role of fibroblasts in regulating epidermal morphogenesis. Cell Tissue Res. 2002; 310(2): 189-99.
16. Trompezinski S., Berthier-Vergnes 0., Denis A. et al. Comparative expression of vascular endothelial growth factor family members, VEGF-B, -C and -D, by normal human keratinocytes and fibroblasts. Exp. Dermatol. 2004; 13(2): 98-105.
17. Bauer S.M., Bauer R.J., Liu Z.J. et al. Vascular endothelial growth factor-C promotes vasculogenesis, angiogenesis, and collagen constriction in three-dimensional collagen gels. J. Vase. Surg. 2005; 41 (4): 699-707
18. Chu A.J., Prasad J.K. Up-regulation by human recombinant transforming growth factor beta-1 of collagen production in cultured dermal fibroblasts is mediated by the inhibition of nitric oxide signaling. J. Am. Coll. Surg. 1999; 188(3): 271-80.
19. Palmon A., Roos H., Edel J. et al. Inverse dose- and timedependent effect of basic fibroblast growth factor on the gene expression of collagen type I and matrix metalloproteinase-1 by periodontal ligament cells in culture. J. Perio-dontol. 2000; 71(6): 974-80.
20. Ali-BaharM., Bauer В., Tredget E.E., GhaharyA. Dermal fibroblasts from different layers of human skin are heterogeneous in expression of collagenase and types I and III procollagen mRNA. Wound Repair Regen. 2004; 12(2): 175-82.
21. Palaiologou A.A., Yukna R.A., Moses R, Lallier Т.Е. Gingival, dermal, and periodontal ligament fibroblasts express different extracellular matrix receptors. J. Periodontol. 2001; 72(6): 798-807.
22. Hirt-Burri N., Scaletta C, Gerber S. et al. Wound-healing gene family expression differences between fetal and foreskin cells used for bioengineered skin substitutes. Artif. Organs 2008; 32(7): 509-18.
23. Chang H.Y., Chi J.Т., Dudoit S. et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. PNAS USA 2002; 99(20): 12877-82.
24. Rinn J.L., Bondre C, Gladstone H.B. et al. Anatomic demarcation by positional variation in fibroblast gene expression programs. PLoS Genet. 2006; 2(7): 119.
25. Okazaki М., Yoshimura К., Suzuki Y., Harii К. Effects of subepithelial fibroblasts on epithelial differentiation in human skin and oral mucosa: heterotypically recombined organotypic culture model. Plast. Reconstr. Surg. 2003; 112(3): 784-92.
26. Yamaguchi Y., Hearing V.J., Itami S. et al. Mesenchymal-epithelial interactions in the skin: aiming for site-specific tissue regeneration. J. Dermatol. Sci. 2005; 40(1): 1-9.
27. Werner S., Krieg Т., Smola H. Keratinocyte-fibroblast interactions in wound healing. J. Invest. Dermatol. 2007; 127(5): 998-1008.
28. Vyalov S.L., Pshenistov K.P., Kuindoz P. i dr. Sovremennye predstavleniya o regulyacii processa zazhivleniya ran: obzor lit. Annaly plast., rekonstr., jestet, hirurgii. 1999; 1: 49-56.
29. Grose R., Werner S. Wound healing studies in transgenic and knockout mice. A review. Methods Mol. Med. 2003; 78: 191-216.
30. Desmouliere A., Geinoz A., Gabbiani F., Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol. 1993; 122(1): 103-11.
31. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J. Pathol. 2003; 200(4): 500-3.
32. Messadi D.V., Doung H.S., Zhang Q. et al. Activation of NF-kappaB signal pathways in keloid fibroblasts. Arch. Dermatol. Res. 2004; 296(3): 125-33.
33. Bitzer M., von Gersdorff G., Liang D. et al. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. Genes Dev. 2000; 14(2): 187-97.
34. Nagarajan R.P., Chen F., Li W. et al. Repression of transforming-growth-factor-beta-mediated transcription by nuclear factor kappa B. Biochem. J. 2000; 348(3): 591-6.
35. Verrecchia F., Pessah M., Atfi A., Mauviel A. Tumor necrosis factor-alpha inhibits transforming growth factor-beta/Smad signaling in human dermal fibroblasts via AP-1 activation. J. Biol. Chem. 2000; 275(39): 30226-31.
36. Guidry C, Grinnell F. Studies on the mechanism of hydrated collagen gel reorganization by human skin fibroblasts. J. Cell Sci. 1985; 79: 67-81.
37. Desmouliere A., Chaponnier C, Gabbiani G. Tissue repair, contraction, and the myofibroblast. Wound Repair Regen. 2005; 13(1): 7-12.
38. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 1961; 25: 585-621.
39. Theobald V.A., Lauer J.D., Kaplan F.A. et al. «Neutral allografts» -lack of allogeneic stimulation by cultured human cells expressing MHC class I and class II antigens. Transplant. 1993; 55(1): 128-33.
40. Bajrejter K., Franc P.I., Rodeman H.P. Fibroblasty pri normal'noj i patologicheskoj terminal'noj differencirovke, starenii, apoptoze i transformacii. Ontogenez 1995; 26: 22-37.
41. Suzdal'ceva Ju.G., Burunova V.V., Vahrushev I.V. i dr. Sravnitel'nyj analiz citofenotipov, sposobnosti k differencirovke i immunologicheskie svojstva kletok mezenhimal'nogo ryada v kul'turah postnatal'nyh organov i tkanej cheloveka. Vserossijskaya i mezhdunarodnaya nauchnaya konferenciya «Stvolovye kletki i perspektiva ih ispol'zovaniya v zdravoohranenii», 30-31 maya 2007; Moskva.
42. Smirnova I.O. Funkcional'naya morfologiya stareniya kozhi. Usp. gerontol. 2004; 13: 44-51.
43. Schneider E.L, Mitsui Y. The relationship between in vitro cellular aging and in vivo human age. PNAS USA 1976; 73(10): 3584-8.
44. Terehov SM. Klonal'nyj analiz pri izuchenii nasledstvennoj patologii. Dis. ...kand. biol. nauk, Moskva, 1984.
45. Cristofalo V.J., Allen R.G., Pignolo R.J. et al. Relationship between donor age and the replicative lifespan of human cells in culture: a reevaluation. PNAS USA 1998; 95(18): 10614-9.
46. Freedland M., Karmiol S., Rodriguez J. et al. Fibroblast responses to cytokines are maintained during aging. Ann. Plast. Surg. 1995; 35(3): 290-6.
47. Chajchir A., Fabrizio D., Chajchir G., Celi E. Growth factors in plastic surgery. Aesthetic Plast. Surg. 2005; 29(4): 295-9.
48. El Ghalbzouri A., Commandeur S., Rietveld M.H. et al. Replacement of animal-derived collagen matrix by human fibroblast-derived dermal matrix for human skin equivalent products. Biomat. 2009; 30(1): 71-8.
49. Atiyeh B.S., Hayek S.N., Gunn S.W. New technologies for burn mound closure and healing - review of the literature. Burns 2005; 31 (8): 944-56.
50. George J., OnoderaJ., MiyataT. Biodegradable honeycomb collagen scaffold for dermal tissue engineering. J. Biomed. Mater. Res. 2008; 87 (4): 1103-11.
51. Yoon E.S., Han S.K., Kim W.K. Advantages of the presence of living dermal fibroblasts within restylane for soft tissue augmentation. Ann. Plast. Surg. 2003; 51(6): 587-92.
52. Mansbridge J. Skin tissue engineering. J. Biomater. Sci. Polym. Ed. 2008; 19(8]: 955-68.
53. Nolte S.V., Xu W, Rennekampff H.O., Rodemann H.P. Diversity of fibroblasts - a review on implications for skin tissue engineering. Cells Tissues Organs 2008; 187(3): 165-76.
54. Waymack P., Duff R.G., Sabolinski M. The effect of a tissue engineered bilayered living skin analog, over meshed split-thickness autografts on the healing of excised burn wounds. The Apligraf Burn Study Group. Burns. 2000; 26(7): 609-19.
55. Kirsner R.S. The use of Apligraf in acute wounds. J. Dermatol. 1998; 25(12): 805-11.
56. Trent J.F., Kirsner R.S. Tissue engineered skin: Apligraf, a bi-layered living skin equivalent. Int. J. Clin. Pract. 1998; 52(6): 408-13.
57. Smirnov SV., Kiselev I.V., Vasil'ev A.V., Terskih V.V. Sovremennye metody kletochnoj terapii pri lechenii ozhogov. Hirurgiya 2003; 12: 58-62.
58. Lapin A.Ju., Topuzov Je.G., Pinaev G.P., Rubcov M.A. Zamestitel'naya kletochnaya terapiya v lechenii troficheskih yazv, vyzvannyh hronicheskoj venoznoj nedostatochnost'ju. Stacionarozamewajuwie tehnologii. Ambulatornaya hirurgiya 2007; 1: 24-6.
59. Lee D.Y., Lee J.H., Yang J.M. et al. A new dermal equivalent: the use of dermal fibroblast culture alone without exogenous materials. J. Dermatol. Sci. 2006; 43(2): 95-104.
60. Gibbs S., van den Hoogenband H.M., Kirtschig G. et al. Autologous full-thickness skin substitute for healing chronic wounds. Br. J. Dermatol. 2006; 155(2): 267-74.
61. Keller G., Sebastian Dzh., Lakombe Ju. i dr. Sohrannost' in#eciruemyh autologichnyh chelovecheskih fibroblastov. Bjul. jeksperiment, biol. med. 2000; 130(8): 203-6.
62. Weiss R.A., Weiss М.А., Beasley K.L., Munavalli G. Autologous cultured fibroblast injection for facial contour deformities: a prospective, placebo-controlled, Phase III clinical trial. Dermatol. Surg. 2007; 33(3): 263-8.
63. Nie X., Zhang J.Y., Cai K.J. et al. Cosmetic improvement in various acute skin defects treated with tissue-engineered skin. Artif. Organs. 2007; 31(9): 703-10.
64. Phillips T.J., Gilchrest B.A. Cultured epidermal allografts as biological wound dressings. Prog. Clin. Biol. Res. 1991; 365: 77-94.
65. Badiavas E.V., Paquette D, Carson P, Falanga V. Human chronic wounds treated with bioengineered skin: histologic evidence of host-graft interactions. J. Am. Acad. Dermatol. 2002; 46(4): 524-30.
66. Yonezawa M., Tanizaki H., Inoguchi N. et al. Clinical study with allogeneic cultured dermal substitutes for chronic leg ulcers. Int. J. Dermatol. 2007; 46(1): 36-42.
67. Griffiths M., Ojeh N., Livingstone R. et al. Survival of Apligraf in acute human wounds. Tissue Eng. 2004; 10(7-8): 1180-95.
68. Lamme E.N., van Leeuwen R.T., Mekkes J.R., Middelkoop E. Allogeneic fibroblasts in dermal substitutes induce inflammation and scar formation. Wound Repair Regen. 2002; 10(3): 152-60.
69. Morimoto N., Saso Y., Tomihata K. et al. Viability and function of autologous and allogeneic fibroblasts seeded in dermal substitutes after implantation. J. Surg. Res. 2005; 125(1): 56-67.
70. Mansbridge J. Commercial considerations in tissue engineering. J. Anat. 2006; 209(4): 527-32.
71. Bochkov N.P. Kletochnaya terapiya v svete dokazatel'noj mediciny. Klin. med. 2006; 10: 4-9.
72. Navsaria Н.А., Myers S.R., Leigh I.M., McKay LA. Culturing skin in vitro for wound therapy. Trends Biotechnol. 1995; 13(3): 91-100.
73. Burunova V.V., Suzdal'ceva Ju.G., Cheglakov I.B. i dr. Podhody k pasportizacii i obespechenie bezopasnosti pri rabote s kletochnymi materialami. Tezisy doklada na konf.: Stvolovye kletki: zakonodatel'stvo, issledovaniya i innovacii. Mezhdunarodnye perspektivy sotrudnichestva. 15-16 marta 2007; Moskva.
74. Hollstein М.С., Peri L, Mandard A.M. et al. Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations. Cancer Res. 1991; 51(15): 4102-6.
75. Watson D., Keller G.S, Lacombe V. Autologous Fibroblasts for Treatment of Facial Rhytids and Dermal Depressions. Arch. Facial Plast. Surg. 1999; 1: 165-17.
76. Boss W.K. Jr, Usal H, Fodor P.В., Chernoff G. Autologous cultured fibroblasts: a protein repair system. Ann. Plast. Surg. 2000; 44(5): 536-42.
77. Bochkov N.P. Citogeneticheskij kontrol' bezopasnosti stvolovyh kletok. Tezisy doklada na konf.: Stvolovye kletki: zakonodatel'stvo, issledovaniya i innovacii. Mezhdunarodnye perspektivy sotrudnichestva. 15-16 marta 2007; Moskva.
78. Bochkov N.P., Nikitina V.A. Citogenetika stvolovyh kletok cheloveka. Molekulyarnaya medicina 2008; 3: 40-7.
79. Kovaleva O.A., Vagina I.N., Morozova L.M. i dr. Geneticheskaya nestabil'nost' i predraspolozhennost' k razvitiju opuholej u laboratornyh linij myshej. Doklady HAH Ukrainy 2007; 2: 158-62.
80. Bochkov N.P. Klassifikaciya i metody ucheta hromosomnyh aberracij v somaticheskih kletkah. M.: Genetika, 1972; 5: 133-41.
81. Rubcov N.B. Hromosomy cheloveka v chetyrjoh izmereniyah. M.: Priroda. 2007; 6: 18-25.
82. Benedetto A.V. The environment and the skin aging. Clin.Dermatol. 1998; 16(1): 129-39.
83. Ditto J., Peknstein E.F. Molecular mechanisms of cutaneous ageing: connective tissue alterations in the dermis. J. Invest. Dermatol. Symp. Proc. 1998; 3(1): 41-4.
84. Fisher G.J., Varani J, Voorhees J.J. Looking older: fibroblast collapse and therapeutic implications. Arch. Dermatol. 2008; 144(5): 666-72.
85. Hertel' B. Molekulyarnye i kletochnye mehanizmy estestvennogo stareniya i fotostareniya (stressornye faktory, zawitnye mehanizmy). Kosmetika i medicina 2000; 4: 5-17.
86. Cooperman L.S. Injectable collagen: a six year clinical investigation. Aesthetic Plast.Surg.1985; 9: 145-51.
87. ApesosJ., Muntzing M.G. Autologen. Clin.Plast.Surg. 2000; 27(4): 507-13.
88. Schmeller W., Meier-Vollrath I. Autologous fat grafting. Hautarzt. 2003; 54(12): 1185-9.
89. Erol 0.0. Facial autologous soft-tissue contouring by adjunction of tissue cocktail injection (micrograft and minigraft mixture of dermis, fascia, and fat). Plast. Reconstr. Surg. 2001; 106(6): 1375-87.
90. Mentz H., Ruiz A., Patronella C, Newall G. Cultured Autologenous Fibroblasts for Wrinkle Reduction. In: Annual Meeting, American Society of Plastic Surgeons, Philadelphia, 2004 Oct.12; Pennsylvania, USA.
91. Zolotovickaya H.H. Jeksperimental'no-klinicheskaya ocenka jeffektivnosti primeneniya kul'tury fibroblastov. V knige: Kolsanov A.V., Ivanova V.D., Volova L.T., Dorozhkina E.B. Klinicheskaya anatomiya i jeksperimental'naya hirurgiya: Ezhegodnik Rossijskoj associacii klinicheskih anatomov v sostave VNOAGJe. Prilozhenie k zhurnalu «Morfologicheskie vedomosti». 2006; 6: 68-73.
92. Remmler D., Thomas J.R., Mazoujian G. et al. Use of injectable cultured human fibroblasts for percutaneous tissue implantation. An experimental study. Arch. Otolaryngol. Head Neck Surg. 1989; 115(7): 837-44.
93. Boss W.K., Marko 0. Isolagen. In: Klein A.W. Ed. Tissue Augmentation in Clinical Practice. New York: Marcel Dekker Inc.; 1998; 335-47.
94. HanS.K., Shin S.H., KangH.J., Kim W.K. Augmentation rhinoplasty using injectable tissue-engineered soft tissue: a pilot study. Ann. Plast. Surg. 2006; 56(3): 251-5.
95. Azolov V.V., Zhegalov V.A., Peretyagin SP. Sostoyanie i perspektivy razvitiya kombustiologii v Rossii. Kombustiologiya 1999; 1: 15-20.
96. Burd A., Yuen С. A global study of hospitalized paediatric burn patients. Burns 2005; 31(4): 432-8.
97. Ermolov A.S, Smirnov SV., Hvatov V.B. i dr. Primenenie biologicheski aktivnyh ranevyh pokrytij, stimulirujuwih regeneraciju jepiteliya ozhogovyh ran IIIA stepeni. Kletochnye tehnologii v biologii i medicine 2008; 3: 166-72.
98. Heinbokel Н.Е., Simon M.R., Jodan М.Н. Cadaver allogratskin supply and demand. Proc. Ann. Burn. Assoc. 1985; 17: 87-95.
99. Gobel P., Schubert W. Our experiences in coverning of juvenile burn injuries with amnion. Beitr. Orthop. Traumatol. 1990; 37(9): 495-8.
100. Mills D.C., Lord W.D. Propofol for repeated burns dressings in child: A case report. Burns 1992; 18: 58-9.
101. Dorling A., LechlerR.I. Prospects for xenografting. Current Opinion in Immunol. 1994; 6(5): 765-9.
102. Germann G., Raff T. Homograft transplantation in severely burned patients. Principles, indications and possibilities. Chirurg. 1995; 66(4): 260-70.
103.Shavga N.G., Loginov L.P., Rejlyan N.S i dr. Klinicheskij jeffekt tkanevoj terapii pri lechenii posleozhogovyh ran. Tezisy doklada na Tret'ej Vsesojuznoj konferencii «Sovremennye sredstva pervoj pomowi i metody lecheniya ozhogovoj bolezni»; 1986; Moskva: 274-276.
104. Hunyadi J., Farkas В., Bertenyi С. et al. Keratinocyte grafting: covering of skin defects by separated autologous keratinocytes in a fibrin net. J. Invest. Dermatol. 1987; 89(1): 119-20.
105. Tumanov V.P., Pal'cin A.A., Sarkisov D.S. Plastika ozhogovyh ran s pomow'ju kul'tivirovannogo jepiteliya. Acta chir. Plast. 1989; 31: 14-20.
106. Compton С.С, Gill J.M., Bradford D.A. et al. Skin regenerated from cultured epithelial autografts on full-thickness burn wounds from 6 days to 5 years after grafting. A light, electron microscopic and immunohistochemical study. Lab. Invest. 1989; 60(5): 600-12.
107. Teepe R.G., Kreis R.W., Koebrugge E.J. et al. The use of cultured autologous epidermis in the treatment of extensive burn wounds. J. Trauma. 1990; 30(3): 269-75.
108. Terskikh V.V., Vasiliev A.V. Cultivation and transplantation of epidermal keratinocytes. Int. Rev. Cytol. 1999; 188: 41-72.
109. De Luca M., Albanese E., Bondanza S. et al. Multicentre experience in the treatment of burns with autologous and allogenic cultured epithelium, fresh or preserved in a frozen state. Burns 1989; 15(5): 303-9.
110. Duinslaeger L., Verbeken G., Reper P. et al. Lyophilized keratinocyte cell lysates contain multiple mitogenic activities and stimulate closure of meshed skin autograft-covered burn wounds with efficiency similar to that of fresh allogeneic keratinocyte cultures. Plast. Reconstr. Surg. 1996; 98(1): 110-7.
111. Oshima H, Inoue H, Matsuzaki К, Tanabe M, Kumagai N. Permanent restoration of human skin treated with cultured epithelium grafting - wound healing by stem cell based tissue engineering. Hum. Cell. 2002; 15(3): 118-28.
112. Sarkisov D.S, Gluwenko E.V., Tumanov V.P. i dr. Opyt primeneniya kul'tury fibroblastov pri lechenii obozhzhennyh. Voen.-med. zhurnal. 1991; 10: 62-3.
113. Fjodorov V.D., Sarkisov D.S, Alekseev A.A. i dr. Primenenie kul'tivirovannyh fibroblastov pri ozhogah kozhi. Vrach 1993; 11: 26-8.
114. Gluwenko E.V. Vosstanovlenie kozhnyh pokrovov u obozhzhjonnyh s pomow'ju kul'tivirovannyh fibroblastov cheloveka. Avtoref. dis. ...kand. med. Moskva 1994.
115. Alekseev A.A., Yashin A.Ju. Kombinirovannaya autodermoplastika s transplantaciej kul'tivirovannyh allofibroblastov pri obshirnyh glubokih ozhogah: klinicheskie rezul'taty i perspektivy. Doklad na Mezhdunarodnom simpoziume «Novye metody lecheniya ozhogov s ispol'zovaniem kul'tivirovannyh kletok kozhi». 1996; Tula
116. Matchin E.N., Potapov V.I., Alekseev A.A. Kliniko-morfologicheskaya ocenka rezul'tatov kombinirovannoj autodermopla-stiki s transplantaciej kul'tivirovannyh allofibroblastov u obozhzhennyh. Kombustiologiya 2000; 2: 35-42.
117. Sarkisov D.S., Alekseev A.A, Tumanov V.P. i dr. Pyatnadcatiletnij opyt ispol'zovaniya kul'tivirovannyh fibroblastov dlya lecheniya tyazheloobozhzhennyh. Tezisy na II Mezhdunarodnom kongresse «Novye metody lecheniya ozhogov s ispol'zovaniem kul'tivirovannyh kletok kozhi». 1998; Saratov.
118. De Lapp, Dieckman D.K. Effect of basic fibroblast growth factors type I [IGF-D and insulin-like growth factors type I (IGF-I) and type II (IGF-II) on adult human keratinocyte growth and fibronectin secretion. J. Invest. Dermat. 1990; 94(6): 817-22.
119. Vozdvizhenskij SI., Budkevich L.I., ShurovaL.V. Organizaciya jetapnoj medicinskoj pomowi detyam rannego vozrasta s termicheskoj travmoj. Tezisy na VII Vserossijskoj nauchno-prakticheskoj konferencii po probleme termicheskih porazhenij. 1999; Chelyabinsk.
120. Matchin E.N., Potapov V.P., Ogol'cova V.A., Kuz'ko Ju.N. Kliniko-gistologicheskie rezul'taty kozhnoj autoplastiki tradicionnymi metodami i s ispol'zovaniem kletochnoj kul'tury fibroblastov. Tezisy na II Mezhdunarodnom kongresse «Novye metody lecheniya ozhogov s ispol'zovaniem kul'tivirovannyh kletok kozhi» 1998; Saratov.
121. Alejnik D.Ya., Aminev V.A., Charykova I.N., Kuvakina N.A. Ispol'zovanie sovremennyh biotehnologij dlya lecheniya poverhnostnyh ozhogov u detej mladshego vozrastaju. Tezisy na II Mezhdunarodnom kongresse «Novye metody lecheniya ozhogov s ispol'zovaniem kul'tivirovannyh kletok kozhi» 1998; Saratov.
122. Kuznecov N.M., Mazka O.N., Shanina L.N. i dr. Primenenie kul'tivirovannyh kletok dlya zakrytiya defektov kozhi. Tezisy na II Mezhdunarodnom kongresse «Novye metody lecheniya ozhogov s ispol'zovaniem kul'tivirovannyh kletok kozhi» 1998; Saratov.
123. Asselineau D., Bernard В.A., Bailly С. et al. Human epidermis recon-structed by culture: is it «normal»? J. Invest. Dermatol. 1986; 86(2): 181-6.
124. NanchahalJ., OttoW.R., Dover R, Dhital S.K. Cultured composite skin grafts: biological skin equivalents permitting massive expansion. Lancet 1989; 2(8656): 191-3.
125. Dvorankova В., Holikova Z., Vacik J. et al. Reconstruction of epidermis by grafting of keratinocytes cultured on polymer support - clinical study. Int. J. Dermatol. 2003; 42(3): 219-23.
126. Tumanov V. Sovremennye kletochnye tehnologii v hirurgii. Jesteticheskaya medicina: nauchno-prakticheskij zhurnal 2003; 2(1): 65-75.
127. Vin F. Troficheskie yazvy nizhnih konechnostej. Flebolimfologiya 1998; 7: 10-2.
128. Archambeau J.О., Ines A, Fajardo L.F. Correlation of the dermal mi-crovasculature morphology with the epidermal and the endothelial population changes produced by single X ray fractions of 1649, 2231 and 2619 rad in swine. Int. J. Radiat. Oncol. Biol. Phys. 1985; 11(9): 1639-46.
129. Hopewell J.W. Radiation Effects on vascular tissue. In: Potten С S., editor. Cytotoxic Insult to Tissue: Effects on Cell Lineages. Edinburgh: Churchill Livingstone; 1983: 228-57.
130. Lewis Т., Zotterman Y. Vascular reactions of the skin to injury: Part VIII. The resistance of the human skin to constant currents, in relation to injury and vascular response. J. Physiol. 1927; 62(3): 280-8.
131. Barabanova A.V., Gus'kova A.K. Znachenie raspredeleniya poglowennyh doz v ob#eme v ishode luchevogo porazheniya. Med. radiologiya. 1982; 11: 53-7.
132. Kirienko A.I., Grigoryan R.A., Bogachev V.Ju., Bogdanec L.I. Farmakoterapiya hronicheskoj venoznoj nedostatochnosti nizhnih konechnostej. Consilium medicum 2000; 2(4): 16-22.
133. Yablokov E.G., Kirienko A.I., Bogachev V.Ju. Hronicheskaya venoznaya nedostatochnost'. M.: Bereg. 1999.
134. Bardychev M.S., Cyb A.F. Mestnye luchevye povrezhdeniya. M.: Medicina, 1985.
135. Stanley А.С., Park H.Y., Phillips T.J. et al. Reduced growth of dermal fibroblasts from chronic venous ulcers can be stimulated with growth factors. J. Vase. Surg. 1997; 26(6): 994-9.
136. Kim B.C., Kim H.T., Park S.H. et al. Fibroblasts from chronic wounds show altered TGF-beta-signaling and decreased TGF-beta Type II receptor expression. J. Cell Physiol. 2003; 195(3): 331-6.
137. Loots M.A., Lamme E.N., Mekkes J.R. et al. Cultured fibroblasts from chronic diabetic wounds on the lower extremity (non-insulin-dependent diabetes mellitus) show disturbed proliferation. Arch. Dermatol. Res. 1999; 291(2-3): 93-9.
138. Riedel K., Koellensperger E., Ryssel H. et al. Abrogation of TGF-beta by antisense oligonucleotides modulates expression of VEGF and increases angiogenic potential in isolated fibroblasts from radiated skin. Int. J. Mol. Med. 2008; 22(4): 473-80.
139. Tattini C, Manchio J., Zaporojan V. et al. Role of TGF-beta and FGF in the treatment of radiation-impaired wounds using a novel drug delivery system. Plast. Reconstr. Surg. 2008; 122(4): 1036-45.
140. MotomuraK., HagiwaraA., Komi-Kuramochi A. et al. An FGF1 :FGF2 chimeric growth factor exhibits universal FGF receptor specificity, enhanced stability and augmented activity useful for epithelial proliferation and radiopro-tection. Biochimica et Biophysica Acta. 2008; 1780: 1432-40.
141. Shi C, Cheng Т., Su Y. et al. Transplantation of dermal multipotent cells promotes survival and wound healing in rats with combined radiation and wound injury. Radiat Res. 2004; 162(1): 56-63.
142. Chunmeng S., Tianmin C, Yongping S. et al. Effects of dermal multipotent cell transplantation on skin wound healing. J. Surg. Res. 2004; 121(1): 13-9.
143. Falanga V. Apligraf treatment of venous ulcers and other chronic wounds. J. Dermatol. 1998; 25(12): 812-7.
144. Yonezawa M., Tanizaki H., Inoguchi N. at al. Clinical study with allogeneic cultured dermal substitutes for chronic leg ulcers. Int. J. Dermatol. 2007; 46(1): 36-42.
145. Wieman T.J. Introduction to care of chronic wounds. Am. J. Surg. 1998; 176(2A): 1S-2S.
146. Marston W.A., Hanft J., Norwood P., Pollak R. Dermagraft Diabetic Foot Ulcer Study Group. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. 2003; 26(6): 1701-5.
147. Veves A., Falanga V., Armstrong D.G., Sabolinski M.L. Apligraf Diabetic Foot Ulcer Study. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001; 24(2): 290-5.
148. CaravaggiC, De Giglio R., Pritelli С atal. HYAFF 11-based autologous dermal and epidermal grafts in the treatment of noninfected diabetic plantar and dorsal foot ulcers: a prospective, multicenter, controlled, randomized clinical trial. Diabetes Care. 2003; 26(10): 2853-9.
149. Cavallini M. Autologous fibroblasts to treat deep and complicated leg ulcers in diabetic patients. Wound Repair Regen. 2007; 15(1): 35-8.
150. de Imus G., Golomb C., Wilkel С. et al. Accelerated healing of pyoderma gangrenosum treated with bioengineered skin and concomitant immunosuppression. J. Am. Acad. Dermatol. 2001; 45(1): 76.
151. Flores F., Eaglstein W.A., Kirsner R.S. Hydroxyurea-induced leg ulcers treated with Apligraf. Ann. Intern. Med. 2000; 132(5): 417-8.
152. Martin L.K., Kirsner R.S. Ulcers caused by bullous morphea treated with tissue-engineered skin. Int. J. Dermatol. 2003; 42(5): 402-4.
153. Streit M., Bohlen L.M., Braathen L.R. Ulcerative sarcoidosis successfully treated with apligraf. Dermatology 2001; 202(4): 367-70.
154. Eisenberg M., Llewelyn D. Surgical management of hands in children with recessive dystrophic epidermolysis bullosa: use of allogeneic composite cultured skin grafts. Br. J. Plast. Surg. 1998; 51(8): 608-13.
155. Fivenson D.P., Scherschun L, Cohen L.V. Apligraf in the treatment of severe mitten deformity associated with recessive dystrophic epidermolysis bullosa. Plast. Reconstr. Surg. 2003; 112(2): 584-8.
156. Woodley D.T., Krueger G.G., Jorgensen CM. et al. Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J. Invest. Dermatol. 2003; 121(5): 1021-8.
157. 157. Wong Т., Gammon L., Liu L. et al. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J. Invest. Dermatol. 2008; 128(9): 2179-89.
158. 1 58. Ortiz-Urda S., Lin Q, Green C.L. et al. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J. Clin. Invest. 2003; 111(2): 251-5.